What one share of Lucid Diagnostics holds
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”).
Lucid Diagnostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.04 |
|---|---|
| Profit | −$0.46 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.34 |
| Cash and investments | $0.18 |
| Book value | $0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.59 | — | — | — | −$0.96 |
| 2021 | $0.03 | −$1.51 | $0.05 | −$1.00 | — | $1.57 |
| 2022 | $0.01 | −$1.55 | $0.09 | −$0.91 | — | $0.57 |
| 2023 | $0.06 | −$1.26 | — | — | — | −$0.05 |
| 2024 | $0.09 | −$1.05 | $0.01 | −$0.88 | — | $0.09 |
| 2025 | $0.05 | −$0.69 | $0.00 | −$0.46 | — | $0.08 |
Common questions about Lucid Diagnostics
How much does one share of Lucid Diagnostics earn?
Over the last 12 months, Lucid Diagnostics lost $0.46 for each share on $0.04 of sales.
Does Lucid Diagnostics pay a dividend?
Lucid Diagnostics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Lucid Diagnostics’s book value per share?
Lucid Diagnostics’s book value is $0.06 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Lucid Diagnostics have?
Each share of Lucid Diagnostics has $0.18 of cash and investments, as of June 30, 2026.
What is Lucid Diagnostics’s free cash flow per share?
−$0.34 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Lucid Diagnostics bought back shares?
Lucid Diagnostics’s share count rose about 622% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.